Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

Cited by (1,003)

Items 701–800 of 1,003

1. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
   Lorenzo Gervaso, Davide Ciardiello, Rivadavio Antunes Oliveira, Michele Borghesani, Lorenzo Guidi, Lavinia Benini, Laura Algeri, Francesca Spada, Maria Giulia Zampino, Chiara Alessandra Cella et al. · 2024 · Journal for ImmunoTherapy of Cancer
2. Biological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite
   Qing Zhen Yang, Ruize Qu, Siyi Lu, Yi Zhang, Zhipeng Zhang, Wei Fu · 2024 · International Journal of Medical Sciences
3. Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status
   Yingjie Li, Luxin Tan, Nan Chen, Xinzhi Liu, Fei Liang, Yunfeng Yao, Xiao Yan Zhang, Aiwen Wu · 2024 · Diseases of the Colon & Rectum
4. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
   Hisato Kawakami, Shuichi Hironaka, Taito Esaki, Kazuaki Chayama, Masahiro Tsuda, Naotoshi Sugimoto, Shigenori Kadowaki, Akitaka Makiyama, Nozomu Machida, Hidekazu Hirano et al. · 2021 · Cancers
5. Industrializing engineered autologous T cells as medicines for solid tumours
   Cedrik Michael Britten, Aiman M. Shalabi, Axel Hoos · 2021 · Nature Reviews Drug Discovery
6. Pharmacogenomic‐Guided Therapy in Colorectal Cancer
   Robert B. Diasio, Federico Innocenti, Steven M. Offer · 2021 · Clinical Pharmacology & Therapeutics
7. MSI testing
   Josef Rüschoff, Gustavo Bruno Baretton, Hendrik Bläker, Wolfgang Dietmaier, Manfred Dietel, Arndt Hartmann, Lars‐Christian Horn, Korinna Jöhrens, Thomas Kirchner, Ruth Knüchel et al. · 2021 · Der Pathologe
8. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
   Angela Damato, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Francesco Iachetta, Alessandra Romagnani, Erika Gervasi, Mario Larocca, Carmine Pinto · 2021 · Frontiers in Oncology
9. The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors
   Huan Tong, He Wei, Alhaji Osman Smith, Juan Huang · 2022 · Frontiers in Immunology
10. Antibody-drug conjugates: beyond current approvals and potential future strategies
    Siddharth Menon, Sagun Parakh, Andrew Mark Scott, Hui Kong Gan · 2022 · Exploration of Targeted Anti-tumor Therapy
11. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma
    Takeshi Kuwata · 2024 · Pathology International
12. Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity
    Alastair Copland, Gillian M. Mackie, Lisa Scarfe, Elizabeth Jinks, David A.J. Lecky, Nancy H. Gudgeon, Riahne McQuade, Masahiro Ono, Manja Barthel, Wolf‐Dietrich Hardt et al. · 2024 · EMBO Molecular Medicine
13. Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy
    Jing Jiao, You Wu, Shaoxian Wu, Jingting Jiang · 2025 · Current Treatment Options in Oncology
14. Interaction between gut microbiota and T cell immunity in colorectal cancer
    Zhuang Jing, Yinhang Wu, Jian Chu, Qu Zhanbo, Xinyue Wu, Shuwen Han · 2025 · Autoimmunity Reviews
15. BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications
    Hiba Mechahougui, James Gutmans, Roumaïssa Gouasmi, Laure Smekens, Alex Friedlaender · 2025 · International Journal of Molecular Sciences
16. Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions
    Pina Ziranu, Andrea Pretta, Giorgio Saba, Dario Spanu, Clelia Donisi, Paolo Albino Ferrari, Flaviana Cau, Alessandra Pia D’Agata, Monica Piras, Stefano Mariani et al. · 2025 · International Journal of Molecular Sciences
17. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients
    Kemin Ni, Yixiang Zhan, Zhaoce Liu, Xuanzhu Zhao, Wanting “Lisa” Wang, Guihua Wang, Zili Zhang, Guoxun Li, Xipeng Zhang, Chunze Zhang · 2021 · Journal of Surgical Oncology
18. Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis
    Chunhui Jin, Xiaodan Zhu, Xiaona Huang, Tingjie Gong, Zhipeng Wei, Jianliang You · 2022 · Journal of Comparative Effectiveness Research
19. eEF1A1 promotes colorectal cancer progression and predicts poor prognosis of patients
    Ahui Fan, Xiaojuan Zhao, Hao Liu, Danxiu Li, Tongtong Guo, Jiehao Zhang, Lili Duan, Hao Cheng, Yongzhan Nie, Daiming Fan et al. · 2022 · Cancer Medicine
20. Monitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives
    Karmela K Chan, Anne R. Bass · 2022 · Journal of Inflammation Research
21. Radiomic Cancer Hallmarks to Identify High-Risk Patients in Non-Metastatic Colon Cancer
    Damiano Caruso, Michela Polici, Marta Zerunian, Antonella Del Gaudio, Emanuela Parri, Maria Agostina Giallorenzi, Domenico De Santis, Giulia Tarantino, Mariarita Tarallo, Filippo Maria Dentice di Accadia et al. · 2022 · Cancers
22. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non–Small Cell Lung Cancer
    Xing Yi Woo, Anuj Srivastava, Philip C. Mack, Joel H. Graber, Brian J. Sanderson, Michael W. Lloyd, Mandy Chen, Sergii Domanskyi, Regina F. Gandour‐Edwards, Rebekah A. Tsai et al. · 2022 · Cancer Research
23. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
    Hanju Hua, Wenguang He, Nan Chen, Yinjun He, Guosheng S. Wu, Feng Ye, Xile Zhou, Yandong Li, Yongfeng Ding, Weixiang Zhong et al. · 2023 · Frontiers in Immunology
24. Local Control and Survival Outcomes After Stereotactic Radiosurgery for Brain Metastases From Gastrointestinal Primaries: An International Multicenter Analysis
    Raj Bahadur Singh, Greg N. Bowden, David Mathieu, Haley Kopp Perlow, Joshua David Palmer, Shahed Elhamdani, Matthew J. Shepard, Yun Liang, Ahmed M. Nabeel, Wael Abdel Halim Reda et al. · 2023 · Neurosurgery
25. A review on emerging targeted therapies for the management of metastatic colorectal cancers
    Rohitas Deshmukh, Mahendra Kumar Prajapati, Ranjit Kumar Harwansh · 2023 · Medical Oncology
26. Investigating the drug carrying ability of Al and Ga doped B12N12 nanocages for 5-fluorouracil based on DFT
    ShiQuan Wu, Li Li, Qi-Qi Liang, Hua-Xu Gao, De‐Yuan Hu, Tianyu Tang, Yan-Lin Tang · 2023 · New Journal of Chemistry
27. Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive
    Xiaokang Lei, Yinkui Wang, Fei Shan, Shuangxi Li, Yongning Jia, Rulin Miao, Kan Xue, Li Z, Jiafu Ji, Ziyu Li · 2023 · Journal of the Chinese Medical Association
28. Colorectal cancer in patients of advanced age is associated with increased incidence of BRAF p.V600E mutation and mismatch repair deficiency
    Eric Scott Christenson, Hua‐Ling Tsai, Dung Thi Le, Elizabeth M. Jaffee, Jonathan C. Dudley, Rena R. Xian, Christopher D. Gocke, James R. Eshleman, Ming-Tseh Lin · 2023 · Frontiers in Oncology
29. Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
    Ji‐Yeon Kim, Sabin Park, Eun Yoon Cho, Jeong Eon Lee, Hae Hyun Jung, Byung Joo Chae, Seok Won Kim, Seok Jin Nam, Soo Youn Cho, Yeon Hee Park et al. · 2023 · Experimental & Molecular Medicine
30. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
    Yen‐Hao Chen, Ching‐Hua Tsai, Yen‐Yang Chen, Chih‐Chi Wang, Jing‐Houng Wang, Chao‐Hung Hung, Yuan‐Hung Kuo · 2023 · BMC Cancer
31. Serious immune‐related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series
    Clément Bresteau, Pauline Bonnet, Caroline Robert, Charlotte Mussini, Philippe Saïag, Bruno Buecher, Célèste Lebbé, Matthieu Allez, Robert Benamouzig, Hervé Hagège et al. · 2023 · Journal of Gastroenterology and Hepatology
32. Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer
    Lu Wang, Tianyu Zhang, Yile Zheng, Yuting Li, Xiyuan Tang, Qianping Chen, Wei Mao, Weiwei Li, Xiangsheng Liu, Ji Ye Zhu · 2023 · Materials Today Bio
33. Genetic and immune landscape evolution in MMR‐ deficient colorectal cancer
    Benjamin R. Challoner, Andrew Woolston, David K. Lau, Marta Buzzetti, Caroline Fong, Louise J. Barber, Gayathri Anandappa, Richard Crux, Ioannis Assiotis, Kerry Fenwick et al. · 2023 · The Journal of Pathology
34. Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
    Jiang Liu, Degan Liu, Guangyin Hu, Jingjing Wang, Dadong Chen, Chuanjun Song, Yin Cai, Chentong Zhai, Wenjing Xu · 2023 · Cancer Cell International
35. The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine
    Moein Piroozkhah, Yasaman Gholinezhad, Mobin Piroozkhah, Elahe Shams, Ehsan Nazemalhosseini Mojarad · 2023 · Frontiers in Immunology
36. Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis
    Yunlin Jiang, Mingye Zhao, Yue Yin, Xueping Zheng, Wenxi Tang · 2024 · BMC Cancer
37. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non–Small Cell Lung Cancer
    Jeanna Wallenta Law, Bela Bapat, Connor Sweetnam, Hina Mohammed, Ashleigh E. McBratney, Monika A. Izano, Molly Scannell Bryan, Scott Spencer, Brock E. Schroeder, Damon Hostin et al. · 2024 · JCO Precision Oncology
38. Differences in tumor-associated T-cell receptor repertoires between early-onset and average-onset colorectal cancer
    Ya-Yu Tsai, Kanika G. Nair, Shimoli Vipul Barot, Xiang Shao, Suneel Deepak Kamath, Marilena Melas, Christopher Walker, Raghvendra Mohan Srivastava, Nicole Osborne, Timothy An-thy Chan et al. · 2024 · JNCI Journal of the National Cancer Institute
39. Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
    Karam Ashouri, Alexandra Wong, Pooja Mittal, Lesly Torres‐Gonzalez, Jae Ho Lo, Shivani Soni, Sandra D. Algaze, Taline Khoukaz, Wu Zhang, Yan Yang et al. · 2024 · Cancers
40. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial
    Yueyun Chen, Peipei Wang, Yang Hu, Yong Yuan, Yu‐Shang Yang, Shi H, Qing Hao, Zhen Lin, Jiangfang Tian, Yue Zheng et al. · 2024 · British Journal of Cancer
41. Inhibition of IRP2-dependent reprogramming of iron metabolism suppresses tumor growth in colorectal cancer
    Jieon Hwang, Areum Park, Chinwoo Kim, Chang Gon Kim, Jaesung Kwak, Byungil Kim, Hyun‐Jin Shin, Minhee Ku, Jaemoon Yang, Ayoung Baek et al. · 2024 · Cell Communication and Signaling
42. Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results
    Dimitrios C. Ziogas, Charalampos Theocharopoulos, Katerina Aravantinou-Fatorou, Aristeidis E. Boukouris, Dimitra T. Stefanou, Amalia N. Anastasopoulou, Peter Lialios, George Lyrarakis, Helen J Gogas · 2025 · Critical Reviews in Oncology/Hematology
43. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
    Guido Giordano, Pietro Parcesepe, Giuseppina Bruno, Annamaria Piscazzi, Vincenzo Lizzi, Andrea Remo, Massimo Pancione, Mario Rosario D'Andrea, Elena De Santis, Luigi Coppola et al. · 2021 · International Journal of Molecular Sciences
44. Current Approaches in Managing Colonic Serrated Polyps and Serrated Polyposis
    David E. F. W. M. van Toledo, Joep E. G. IJspeert, Evelien Dekker · 2022 · Annual Review of Medicine
45. A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)
    Scott, Aaron J., Basu Mallick, Atrayee, Dotan, Efrat, Cohen, Steven J., Gold, Philip J., Hochster, Howard S., Subramaniam, Somasundaram, Barzi, Afsaneh, Watts, George S., Blatchford, Patrick J. et al. · 2022 · Cancer Research Communications
46. The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
    Jacopo Venturini, Giulia Massaro, Daniele Lavacchi, Daniele Rossini, Serena Pillozzi, Enrico Caliman, Elisa Pellegrini, Lorenzo Antonuzzo · 2024 · Critical Reviews in Oncology/Hematology
47. LRG1-Targeted Camptothecin Nanomicelles with Simultaneous Delivery of Olaparib for Enhanced Colorectal Cancer Chemotherapy
    Lin Du, Huan Min, Yongkang Meng, Kejuan Zhang, Longdi Wang, Yana Zhang, Peichun Sun, Wei Zhang, Yingqiu Qi, Gang Wu · 2025 · Nano Letters
48. Colorectal cancer: highlight the clinical research current progress
    Meng Wang, Chaojing Zheng, Zitong Wang, Ruifen Li, Weiyuan Zhang, Yuchen Zhong, Hongyu Wu, Qian Zhang, Dong Han, Yuping Zhu et al. · 2025 · Holistic Integrative Oncology
49. Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps
    Benita C. Y. Tse, Zoe Welham, Alexander F Engel, Mark P. Molloy · 2021 · Cancers
50. DNA Mismatch Repair–deficient Rectal Cancer Is Frequently Associated With Lynch Syndrome and With Poor Response to Neoadjuvant Therapy
    Lama O. Farchoukh, James P. Celebrezze, David Medich, Kellie Cunningham, Jennifer Holder‐Murray, Matthew Peter Holtzman, Kenneth S. Lee, Haroon Asif Choudry, Reetesh K. Pai · 2022 · The American Journal of Surgical Pathology
51. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation
    Lei Wen, Zhigang Chen, Xiaomeng Ji, William Pat Fong, Qiong Shao, Chao Ren, Yanyu Cai, Binkui Li, Yunfei Yuan, De‐Shen Wang et al. · 2022 · Journal for ImmunoTherapy of Cancer
52. Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis
    Eric Jou, Noé Rodríguez‐Rodríguez, Andrew N. J. McKenzie · 2022 · Frontiers in Immunology
53. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data
    Miao Jiang, Yong-liang Jia, Jinming Han, Jianxiang Shi, Chang Su, Rui Zhang, Menglu Xing, Shuiling Jin, Hong Zong · 2022 · Frontiers in Genetics
54. Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy
    Ajay Prakash, Travis J. Gates, Xianda Zhao, Dechen Wangmo, Subbaya Subramanian · 2022 · Pharmacology & Therapeutics
55. Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
    Yue Li, Baoming Wang, Chunyang Wang, Dandan Zhao, Zhengchuang Liu, Yan-Ling Niu, Xiaojuan Wang, Wei Li, Jianhua Zhu, Hou‐Quan Tao et al. · 2022 · Cancers
56. Recent advances in lanthanide-doped up-conversion probes for theranostics
    Danyang Xu, Chenxu Li, Wenjing Li, Bi Lin, Ruichan Lv · 2023 · Frontiers in Chemistry
57. Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
    Giulia Martini, Davide Ciardiello, Stefania Napolitano, Erika Martinelli, Teresa Troiani, Tiziana Pia Latiano, Antonio Avallone, Nicola Normanno, Massimo Di Maïo, Evaristo Maiello et al. · 2023 · Frontiers in Oncology
58. Exploring the effect of polyamines on NK cell function in colorectal cancer process based on glycolysis
    Huan He, Zijing Song, Siqi Lin, Yu Wang, Guixiang Wang · 2023 · International Immunopharmacology
59. Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials
    Jingyi Hou, Ruiyang Xie, Zhuo Zhang, Qianxin Liu, Qian Xiang, Yimin Cui · 2023 · Frontiers in Pharmacology
60. Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors
    Alexandra Lainé, Andrea María González López, Uzma Ayesha Hasan, Ryotaro Ohkuma, Isabelle Laure Ray-Coquard · 2023 · Cancers
61. Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
    Jingjing Li, Xuanfu Xu · 2023 · International Journal of General Medicine
62. Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials
    Elena Fountzilas, Henry Hiep Vo, Peter J. Mueller, Razelle Kurzrock, Apostolia Maria Tsimberidou · 2022 · European Journal of Cancer
63. KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer
    Thierry André, Filippo Pietrantonio, Antonio Avallone, Mahmut Gümüş, Lucjan Stanislaw Wyrwicz, Jong Gwang Kim, Şuayib Yalçın, Mariusz Kwiatkowski, Sara Lonardi, Jakub Żołnierek et al. · 2023 · Future Oncology
64. Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
    Shiya Yao, Yuejun Han, Mengxiang Yang, Ketao Jin, Huanrong Lan · 2023 · Frontiers in Immunology
65. Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
    Clémence Flecchia, Édouard Auclin, Emily Linda Alouani, Mathilde Mercier, Antoine Hollebecque, Anthony Turpin, Thibault Mazard, Simon Pernot, Marie Dutherage, Romain Cohen et al. · 2023 · British Journal of Cancer
66. Immunotherapy for Ovarian Cancer: Disappointing or Promising?
    Mengqi Deng, Fan Tang, Xiangyu Chang, Penglin Liu, Xuechao Ji, Menglin Hao, Yixiao Wang, Ruiye Yang, Qingqing Ma, Yubo Zhang et al. · 2024 · Molecular Pharmaceutics
67. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer
    Giuseppe Rospo, Rosaria Chilà, Vittoria Matafora, Veronica Basso, Simona Lamba, Alice Bartolini, Angela Bachi, Federica Di Nicolantonio, Anna Mondino, Giovanni Germano et al. · 2024 · Genome Medicine
68. Beta-2-microglobulin Mutations Are Linked to a Distinct Metastatic Pattern and a Favorable Outcome in Microsatellite-Unstable Stage IV Gastrointestinal Cancers
    Elena Busch, Aysel Ahadova, Kosima Kosmalla, Lena Bohaumilitzky, Pauline Luise Pfuderer, Alexej Ballhausen, Johannes Witt, Jan-Niklas Wittemann, Hendrik Bläker, Elke Holinski‐Feder et al. · 2021 · Frontiers in Oncology
69. Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients
    Kristine Aasebø, Jarle Bruun, Christian Holst Bergsland, Luís Nunes, Geir Egil Eide, Per Pfeiffer, Olav Dahl, Bengt L. G. Glimelius, Ragnhild A. Lothe, Halfdan Sørbye · 2021 · British Journal of Cancer
70. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors
    Daniel Schlauch, Xiaotong Fu, Suzanne Fields Jones, Howard A. Burris, David Robert Spigel, James Andrew Reeves, Andrew Jacob McKenzie · 2021 · JCO Precision Oncology
71. ‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors
    Ashray Gunjur, Andrea Manrique-Rincón, Oliver Klein, Andreas Behren, Trevor D. Lawley, Sarah Joanne Welsh, David J. Adams · 2022 · The Journal of Pathology
72. Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook
    Jakub Styk, Zuzana Pös, Ondrej Pös, Ján Radvánszky, Evelina Hrckova Turnova, Gergely Buglyó, Daniela Klimová, Jaroslav Budiš, Vanda Repiská, Bálint Nagy et al. · 2023 · The EPMA Journal
73. Manipulating TGF-β signaling to optimize immunotherapy for cervical cancer
    Shuping Yin, Han Cui, Shuang Qin, Shengnan Yu · 2023 · Biomedicine & Pharmacotherapy
74. Targeting amino acid metabolism to inhibit gastric cancer progression and promote anti-tumor immunity: a review
    Yuchun Jiang, Tao Qing, Xuehan Qiao, Yufei Yang, Peng Chen, Miao Han, Kebin Dong, Wei Zhang, Min Xu, Deqiang Wang et al. · 2025 · Frontiers in Immunology
75. Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review
    Celine Hoyek, Binbin Zheng-Lin, Jennah J. Bauernfeind, Omar Hussain Al-Ahmad, Tanios Bekaii‐Saab, Sakti Chakrabarti, Sawsan Rashdan, Mohamad Bassam Sonbol · 2025 · JCO Global Oncology
76. Early immune evasion in colorectal cancer: interplay between stem cells and the tumor microenvironment
    Norihiro Goto, Judith Agudo, Ömer H. Yilmaz · 2025 · Trends in cancer
77. Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications
    Supriya Peshin, Faizan Bashir, Naga Anvesh Kodali, Adit Alpesh Dharia, Sajida Zaiter, Sakshi Singal, Nagaishwarya Moka · 2025 · Antibodies
78. Icariin modulates the tumor microenvironment in colorectal cancer by targeting M2 macrophage polarization via PI3K/AKT pathway
    Yu Chen, Yue Qi, Yulan Jiang, Ying Li, Shaoxue Yang, Lu Wang, Mingqian Li, Kequn Chai, Yifan Wang · 2025 · Bioorganic & Medicinal Chemistry
79. Neoadjuvant immunotherapy and chemoradiotherapy for mismatch repair proficient locally advanced rectal cancer: A systematic review and meta-analysis
    Yu Wang, Yue Liu, Xu Guan, Xin Liu, Yuan Tang, Wenwen Zhang, Chunxia Du, Shuangmei Zou, Haitao Zhou, Jian-Wei Liang et al. · 2025 · Radiotherapy and Oncology
80. Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
    Marine Jary, Wenwei Liu, Dongyao Yan, Isaac Bai, Andrea Murányi, Elise Colle, Isabelle Brochériou, Anthony Turpin, Nina Radosevic‐Robin, Pierre Bourgoin et al. · 2021 · Molecular Oncology
81. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy
    Saulo Brito Silva, Carlos Wagner S Wanderley, Leandro Machado Colli · 2022 · Frontiers in Immunology
82. mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers
    Lei Cheng, Yanan Wang, Li‐Xin Qiu, Yuanyuan Chang, Haijiao Lu, Chenchen Liu, Bo Zhang, Yan Zhou, Hao Bai, Liwen Xiong et al. · 2022 · Journal of Translational Medicine
83. Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )
    Suki Gill, Anna K. Nowak, Samantha Elizabeth Bowyer, Raelene Endersby, Martin A. Ebert, Alistair Cook · 2022 · Journal of Medical Imaging and Radiation Oncology
84. The emerging era of personalized medicine in advanced colorectal cancer
    Claudia Wing‐Kwan Wu, Madeleine Reid, Simon John Leedham, Rashid Nok-Shun Lui · 2022 · Journal of Gastroenterology and Hepatology
85. Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients
    Thomas K Helmberger, Pierleone Lucatelli, Philippe Lucien Pereira, Aleksandar Gjoreski, Ivona Jovanoska, Zoltán Bánsághi, Stavros Spiliοpoulos, Francesca Carchesio, Dirk Arnold, Andreas Baierl et al. · 2022 · Journal of Clinical Medicine
86. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models
    Julie Lang, Alexis Diane Leal, Juan A. Marín‐Jiménez, Sarah J. Hartman, Jeremy Shulman, Natalie M. Navarro, Matthew S. Lewis, Anna Capasso, Stacey M. Bagby, Bethlehem W. Yacob et al. · 2022 · Frontiers in Oncology
87. The prognostic index of m7G-related genes in CRC correlates with immune infiltration
    Xinkun Huang, Bin Zhu, Chenyu Qian, Ying Feng · 2022 · Scientific Reports
88. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
    Daniele Lavacchi, Giandomenico Roviello, Alessia Guidolin, Silvia Romano, Jacopo Venturini, Enrico Caliman, Agnese Vannini, Elisa Giommoni, Elisa Pellegrini, Marco Brugia et al. · 2023 · International Journal of Molecular Sciences
89. A novel prognostic signatures based on metastasis- and immune-related gene pairs for colorectal cancer
    Bei Pan, Yanzhe Yue, Wenbo Ding, Li Sun, Mu Xu, Shukui Wang · 2023 · Frontiers in Immunology
90. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy
    Ying Yang, Wenjian Meng, Ziqiang Wang · 2023 · Frontiers in Bioscience-Landmark
91. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer
    Tao Jiang, Linshuai Xing, Lipeng Zhao, Ziqi Ye, Yu Juan Dong, Shengtao Lin · 2023 · BMC Medical Genomics
92. High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer
    Jingjing Guo, Baijie Tang, Jing Fu, Xuan Zhu, Wen-Long Xie, Nan Wang, Zhiyong Ding, Zhentao Song, Yue Yang, Gang Xu et al. · 2023 · Cellular Oncology
93. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination
    Kristen Simmons, Jane Varkey Thomas, Kaysia T. Ludford, Jason A. Willis, Victoria Serpas Higbie, Kanwal P. S. Raghav, Benny Johnson, Arvind N. Dasari, Bryan K. Kee, Christine Megerdichian Parseghian et al. · 2023 · Cancer Research Communications
94. Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study
    Saana Virtanen, Heidi Pihlman, Maria Silvoniemi, Pia Vihinen, Panu Jaakkola, Kalle Mattila · 2024 · Cancers
95. A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids
    Dexter Kai Hao Thng, Lissa Hooi, Bei En Siew, Kai-Yin Lee, Ian Jse-Wei Tan, Bettina Lieske, Norman Sihan Lin, Alfred Wei Chieh Kow, Shi Wang, Masturah Bte Mohd Abdul Rashid et al. · 2024 · npj Precision Oncology
96. Colorectal Cancer Pulmonary Metastasectomy: When, Why and How
    Francesco Petrella, Federica Danuzzo, Maria Chiara Sibilia, Sara Vaquer, Raffaella Longarini, Alessandro Guidi, Federico Raveglia, Lidia Libretti, Emanuele Pirondini, Andrea Cara et al. · 2024 · Cancers
97. Surgical Resection in Colorectal Liver Metastasis: An Umbrella Review
    Martina Milazzo, Letizia Todeschini, Miriam Caimano, Amelia Mattia, Luca Cristin, Alessandro Martinino, Giuseppe Bianco, Gabriele Spoletini, Francesco Giovinazzo · 2024 · Cancers
98. PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial
    Zehua Wu, Yuan-Zhe Zhang, Yi Cheng, Jianxia Li, Fangqian Li, Chao Wang, Lishuo Shi, Ge Qin, Weixiang Zhan, Yue Cai et al. · 2024 · Med
99. Fusobacterium nucleatum: a novel regulator of antitumor immune checkpoint blockade therapy in colorectal cancer
    Mengjie Luo · 2024 · American Journal of Cancer Research
100. Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer
     Zijian Deng, Yajun Luo, Xiaoli Chen, Tao Pan, Yuanyi Rui, Hai Hu, Jin Yan, Ke Zhang, Cheng Luo, Bo Song · 2024 · Frontiers in Immunology